MEMGEN
Updated 262 days ago
12 Greenway Plaza Suite 1100 Houston, TX 77046
Memgen's mission is to design and develop viral immunotherapies that can be used in combination with market-leading cancer drugs including KEYTRUDA and OPDIVO to cure cancer...
Memgen has built a strong world-wide patent position around our viral immunotherapies which have been re-engineered to kill cancer cells, while sparing healthy cells. MEM-288 is scheduled to begin clinical trials in 2021...
Memgen's immunotherapies leverage the power of our proprietary clinically evaluated CD40 ligand in combination with other co-stimulatory genes. MEM-288, our lead product candidate, combines our CD40 ligand with interferon beta (IFNβ). This combination has been engineered by Memgen and Moffitt Cancer Center to provide the optimum capability to generate a robust, whole-body, tumor-targeted T cell immune response.
Also known as: Memgen, Inc.